Spero R. Cataland

Spero R. Cataland studies rare blood-clotting disorders, especially thrombotic thrombocytopenic purpura (TTP), a condition where tiny blood clots form throughout the body and destroy platelets and red blood cells. His work spans clinical trials of new drugs (like caplacizumab and recombinant ADAMTS13), development of treatment guidelines, and studies of long-term complications such as neurocognitive and cardiac effects in survivors. This research is aimed at improving diagnosis, treatment, and outcomes for patients with TTP and related conditions like atypical hemolytic uremic syndrome.

Publication output has fluctuated over the last decade but shows a recent increase, rising from a low in 2022 to a high in 2024-2025.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026